Table 1 Patient baseline characteristics stratified by prescription of beta-blockers before and after propensity matching.

From: Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis

Variables

Before matching

After matching

No BBs

With BBs

No BBs

With BBs

N

58382

41684

41670

41670

Age (mean, yrs)

60

56*

56.7

56.2

Gender, female %

50.3

51.9*

51.0

51.9

Hemodialysis

82.5

98.5*

97.6

98.5

HTN, %

87.8

91.5*

89.6

91.5

DM, %

40.9

50.4*

48.6

50.4

Dyslipidemia

27.8

44.9*

41.2

44.9

Ischaemic stroke/TIA, %

4.1

7.7*

6.8

7.7

Haemorrhagic stroke, %

3.9

6.0*

5.6

6.0

CAD, %

29.2

50.2*

47.3

50.2

PAD, %

21.9

28.2*

25.6

28.2

CHF hospitalization, %

21.3

27.2*

25.4

27.2

Medications

ACEI/ARB, %

17.8

44.5*

28.9

44.5*

CCBs, %

31.2

53.8*

46.9

53.8

Diuretics, %

33.8

39.2*

38.7

39.2

Statin, %

25.9

31.3*

28.9

31.3

OAD, %

23.3

29.0*

27.7

29.0

Insulin, %

7.3

19.2*

10.2

19.2*

  1. *p < 0.05 compared with the no beta-blocker group.
  2. ACEI, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BBs, beta-blockers; CAD, coronary artery disease; CCBs, calcium channel blocker; DM, diabetes mellitus; HTN, hypertension; HD, hemodialysis; CHF, congestive heart failure; TIA, transient ischaemic accident; OAD, oral anti-diabetic drugs; PAD, peripheral artery disease.
Back to article page